Dalton Greiner Hartman Maher & Co. Acquires New Position in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX)

Share on StockTwits

Dalton Greiner Hartman Maher & Co. acquired a new stake in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 89,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $528,000. Dalton Greiner Hartman Maher & Co. owned approximately 0.58% of Cumberland Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bailard Inc. purchased a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at about $92,000. Acadian Asset Management LLC raised its holdings in shares of Cumberland Pharmaceuticals by 6.9% during the 2nd quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock valued at $665,000 after buying an additional 6,765 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Cumberland Pharmaceuticals by 17.2% during the 2nd quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock valued at $2,118,000 after buying an additional 48,753 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Cumberland Pharmaceuticals by 13.0% during the 2nd quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock valued at $2,813,000 after buying an additional 50,800 shares in the last quarter. 31.03% of the stock is currently owned by institutional investors.

CPIX opened at $5.57 on Friday. The stock’s 50 day simple moving average is $5.29 and its 200 day simple moving average is $5.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.33 and a quick ratio of 1.85. Cumberland Pharmaceuticals, Inc. has a 1 year low of $4.70 and a 1 year high of $7.00. The firm has a market cap of $85.79 million, a price-to-earnings ratio of 32.82 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.02. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 9.87%. The business had revenue of $11.58 million for the quarter, compared to analyst estimates of $12.59 million. As a group, sell-side analysts anticipate that Cumberland Pharmaceuticals, Inc. will post 0.31 EPS for the current year.

In related news, Director Gordon R. Bernard sold 6,309 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $5.46, for a total transaction of $34,447.14. Following the transaction, the director now directly owns 41,862 shares in the company, valued at approximately $228,566.52. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gordon R. Bernard sold 7,471 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $5.77, for a total value of $43,107.67. Following the transaction, the director now owns 59,673 shares in the company, valued at $344,313.21. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 4,495 shares of company stock worth $25,752 and have sold 42,840 shares worth $234,661. 39.38% of the stock is owned by company insiders.

CPIX has been the topic of a number of research reports. ValuEngine cut Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Wednesday, August 21st.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Read More: Return On Assets

Want to see what other hedge funds are holding CPIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX).

Institutional Ownership by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Dalton Greiner Hartman Maher & Co. Purchases Shares of 58,800 AXT Inc
Dalton Greiner Hartman Maher & Co. Purchases Shares of 58,800 AXT Inc
Dalton Greiner Hartman Maher & Co. Acquires New Position in Cumberland Pharmaceuticals, Inc.
Dalton Greiner Hartman Maher & Co. Acquires New Position in Cumberland Pharmaceuticals, Inc.
United Parcel Service, Inc.  Shares Sold by First United Bank Trust
United Parcel Service, Inc. Shares Sold by First United Bank Trust
First United Bank Trust Has $2.14 Million Position in Exxon Mobil Co.
First United Bank Trust Has $2.14 Million Position in Exxon Mobil Co.
Ellenbecker Investment Group Has $1.03 Million Stock Holdings in Microsoft Co.
Ellenbecker Investment Group Has $1.03 Million Stock Holdings in Microsoft Co.
CX Institutional Trims Stock Holdings in XPO Logistics Inc
CX Institutional Trims Stock Holdings in XPO Logistics Inc


© 2006-2019 Ticker Report